SCHEMBL8377270

SCHEMBL8377270

O=C(O)Cn1c(=O)[nH]c(=O)c2ccccc21

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.64
GLA P06280 1/20 0.63
APEX1 P27695 1/20 0.54
LCK P06239 1/20 0.51
PRKACA P17612 1/20 0.51
CSNK2A2 P19784 1/20 0.51
PRKACG P22612 1/20 0.51
PRKACB P22694 1/20 0.51
GSK3B P49841 1/20 0.51
CSNK2B P67870 1/20 0.51
CSNK2A1 P68400 1/20 0.51
DYRK1A Q13627 1/20 0.51
CSNK2A3 Q8NEV1 1/20 0.51
PARP1 P09874 5/20 0.51
AKR1B10 O60218 1/20 0.50
AKR1B1 P15121 1/20 0.50
ALDH1A1 P00352 1/20 0.49
MAPK1 P28482 1/20 0.49
STAT3 P40763 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22693613 0.87 PARP1 (0.56) KDM4EGLALCKPRKACACSNK2A2
SCHEMBL11983439 0.86 PARP1 (0.56) KDM4EGLALCKPRKACACSNK2A2
SCHEMBL13799882 0.84 FABP4 (0.66) KDM4EAPEX1LCKPRKACACSNK2A2
SCHEMBL3540980 0.84 KDM4E (0.60) KDM4EGLAAPEX1LCKPRKACA
SCHEMBL7300140 0.82 FABP4 (0.68) KDM4ELCKPRKACACSNK2A2PRKACG
SCHEMBL8487616 0.82 KDM4E (0.59) KDM4EPARP1ALDH1A1
SCHEMBL2255490 0.80 MEN1 (0.62) KDM4EGLAAPEX1ALDH1A1MAPK1
SCHEMBL10487972 0.80 KDM4E (0.62) KDM4EPARP1ALDH1A1
SCHEMBL8046411 0.79 MAT2A (0.52) AKR1B10AKR1B1
SCHEMBL8890567 0.79 HDAC1 (0.47) KDM4EGLAAPEX1AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6001831-A Process for producing quinazoline derivatives CLARIANT GMBH (DE) 1999-12-14 US claimed
EP-0847392-B1 PROCESS FOR PRODUCING QUINAZOLINE DERIVATIVES CLARIANT GMBH (DE) 1999-12-08 EP claimed
EP-2768822-B1 DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS CHIESI FARM SPA (IT) 2017-12-06 EP disclosed
US-9024027-B2 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2015-05-05 US disclosed
US-9024027-B2 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2015-05-05 US disclosed
US-20130102576-A1 DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2013-04-25 US disclosed
US-20130102576-A1 DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2013-04-25 US disclosed
US-6001831-A Process for producing quinazoline derivatives CLARIANT GMBH (DE) 1999-12-14 US disclosed
US-6001831-A Process for producing quinazoline derivatives CLARIANT GMBH (DE) 1999-12-14 US disclosed
EP-0847392-B1 PROCESS FOR PRODUCING QUINAZOLINE DERIVATIVES CLARIANT GMBH (DE) 1999-12-08 EP disclosed
US-5973189-A Monoesters of carboxymethylene anthranilic acids and process for preparing the same CLARIANT GMBH (DE) 1999-10-26 US disclosed
CN-1194639-A Quinazoline derivatives and their use as anti-inflammatory agents CORIEN CO LTD (DE) 1998-09-30 CN disclosed
EP-0847392-A1 PROCESS FOR PRODUCING QUINAZOLINE DERIVATIVES Clariant GmbH (DE) 1998-06-17 EP disclosed
WO-1997008154-A1 PROCESS FOR PRODUCING QUINAZOLINE DERIVATIVES CLARIANT GMBH (DE) 1997-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130102576-A1 DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS PDE4A, PDE3A, PDE4B KDM4E 1220/4885GLA 852/4885APEX1 602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.